Skip to main content

Gamunex News

FDA Medwatch Alert: Voluntary Lot Withdrawals of Immune Globulin Intravenous (IGIV) and Immune Globulin Subcutaneous (IGSC) for Increased Reports of Allergic/Hypersensitivity Reactions

March 4, 2022 – As a precautionary measure, the following lots of Immune Globulin Intravenous (IGIV) and Immune Globulin Subcutaneous (IGSC) have been voluntarily withdrawn by the manufacturers due...

Talecris Biotherapeutics Receives FDA Approval for Gamunex-C

RESEARCH TRIANGLE PARK , N.C., Oct. 14 /PRNewswire-FirstCall/ – Talecris Biotherapeutics (Nasdaq: TLCR) announced today that the U.S. Food and Drug Administration (FDA) approved Gamunex-C (Immune...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Chronic Lymphocytic Leukemia (CLL), Idiopathic (Immune) Thrombocytopenic Purpura, HIV Infection, Myasthenia Gravis